Clinical Scorecard: Impact of Cumulative Social Disadvantage on Disease Severity in Juvenile Idiopathic Arthritis: Findings from a Childhood Arthritis and Rheumatology Research Alliance Registry Analysis

At a Glance

Key Highlights

• Cumulative social disadvantage is associated with higher disease activity in JIA.
• Neighborhood-level deprivation mediates the effect of individual and family-level SDOH.
• The study uses a socioecological model to analyze health disparities in JIA.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of JIA should be made by a pediatric rheumatologist according to ILAR classification criteria.

Management

• Consider the impact of social determinants of health in the management of JIA.

Monitoring & Follow-up

• Regular follow-up visits every six months are recommended for children enrolled in the CARRA Registry.

Risks

• Higher disease activity is linked to economic disadvantage and delays in treatment among publicly insured patients.

Patient & Prescribing Data

Children with JIA enrolled in the CARRA Registry.

Improvements in therapies, including bDMARDs, have enhanced long-term outcomes.

Clinical Best Practices

• Utilize a cumulative social disadvantage score to assess risk in JIA patients.
• Implement multilevel interventions to address health disparities in JIA.

Related Resources & Content

• CARRA Registry